Press Releases

Bioactive Matrixes Products Covering the Full Range Are Now Available at CD Bioparticles

As an established drug delivery company focusing on the development and production of drug delivery systems, CD Bioparticles has released a variety of bioactive matrixes covering reagents&assays, responsive hydrogels, functional biomatrixes and photocrosslinkable kits.

BioIVT Offers Expedited Delivery of Immune Cell Products for Cell and Gene Therapy Research, Drug Discovery and Diagnostic Development

BioIVT now provides same-day or next-day global delivery of fresh blood and immune cell products from its seven blood donor centers located in the US and UK.

Chemical Drug Development Service Now Available at AI & Medicine

As an expert in AI-assisted drug discovery, AI & Medicine recently announces to provide chemical drug development service for researchers worldwide. The powerful AI-assisted drug discovery platform independently developed by this company has already been adopted by a few pharmaceutical companies in their drug R&D endeavors of innovative therapies.

Alfa Chemistry Catalysts—an Expert in Catalysts Science

To better meet the ever-increasing demand for catalysts in the market, Alfa Chemistry Catalysts is founded and specialized in providing various categories of catalysts, including chiral catalysts, ligands, metal catalysts, non-metal catalysts, organocatalysts, phase transfer catalysts, photocatalysts, and reaction type.

Latest Updates: CAR Design and Construction Services Are Optimized at Creative Biolabs

Based on the leading CellRapeuticsTM CAR technology platform, Creative Biolabs has optimized the CAR design and construction services, especially for CAR-T therapy and CAR-NK therapy.

Creative Diagnostics Offers High-quality Magnetic Silica Particles for DNA & RNA Isolation

Creative Diagnostics has released high-quality magnetic silica particles for the isolation of nucleic acid (DNA, RNA) as well as large versus small fragments from various kinds of body fluids, which just takes 3 seconds for complete separation.

Noxopharm Announces New Research Showing Veyonda® Cancer Survival Rates

Australian clinical-stage drug development company Noxopharm is pleased to announce peer-reviewed publication of research showing that in late-stage prostate cancer patients who have exhausted all standard treatment options, a combination of 177Lu-PSMA-617 and Veyonda® is both safe and delivered promising efficacy outcomes, among them a median overall survival of 17.1 months.

BOC Sciences Released A New Antibody-drug Conjugate Technology Platform

Alfa Chemistry Materials—a New Option of Material Building Blocks

Alfa Chemistry Materials, always aiming to be a trust-worthy supplier of material chemicals, recently announces to provide a comprehensive collection of material building blocks for clients worldwide, including: ligands for functional metal complexes, liquid crystal (LC) building blocks, phthalocyanine building blocks, small molecule semiconductor building blocks, solubility enhancing reagents, supramolecular host materials, and other material building blocks.

Spring Bank Pharmaceuticals and F-star Therapeutics Agree to Combine to Pursue Mission of Creating Next Generation Immunotherapies

Spring Bank Pharmaceuticals and F-star Therapeutics, Limited (“F-star”), a privately-held clinical-stage biopharmaceutical company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific (mAb2™) antibodies, today announced that the companies have entered into a definitive share exchange agreement pursuant to which Spring Bank will, subject to stockholder approval, acquire all of the outstanding share capital of F-star in exchange for newly issued shares of Spring Bank in an all-stock transaction. The combined company, operating under the name F-star Therapeutics, Inc., will advance its immuno-oncology pipeline of multiple tetravalent bispecific antibody programs, as well as Spring Bank’s STING (STimulator of INterferon Gene) agonist, SB 11285, currently in a Phase 1/2 clinical trial.

Accumen Releases First FDA EUA COVID-19 Saliva Testing Kits

Accumen Inc. is partnering with medical equipment manufacturer, Spectrum Solutions, to provide COVID-19 saliva testing kits nationally.

CD Genomics Releases Oral Sample Collection Products to Help the Collection and Preservation of Oral Cells

Research Presentation Strategies Is Now SlideSource

Research Presentation Strategies (RPS), a leader and innovator in the design and technology to support regulatory and pharmaceutical presentations, is pleased to announce it will now be known as SlideSource. The newly named company will also feature the leading slide and presentation management tool formally known as SlideSource.com.

Creative Proteomics Launches Untargeted Metabolomics Services for Drug Development

Creative Enzymes Releases Biocatalysis Services for Process of Biocatalyst Development

Clinical Ink Announces Its Acquisition by GI Partners

Clinical Ink today announced its acquisition by GI Capital Partners, accelerating the momentum of the industry’s eSource leader.

Cinda Orr Named PharmaVOICE Top 100 Honoree

SCORR Marketing, the leading full-service marketing and communications firm in the health science industry, is proud to announce that the company’s CEO, Cinda Orr, has been included among PharmaVOICE Magazine’s 100 most inspiring individuals in the life sciences industry.

Panthera’s UK oncology clinical trial sites open for studies

Panthera's UK oncology clinical trial sites are open despite 1000+ international cancer trials being suspended due to COVID-19.

VantAI and TARA Biosystems Partner to Discover New Medicines

Over 300 Clinical Studies Benefit from CluePoints COVID-19 Risk Management Support

CluePoints, the premier provider of Risk-Based Study Execution (RBx) and Data Quality Oversight Software for clinical trials, today announced the success of its complimentary COVID-19 risk management package alongside comprehensive support for COVID-19 affected trials. Launched in April in the wake of COVID-19, the support package includes a widely used online Risk Assessment and Control solution that can be leveraged for performing risk planning and mitigation activities addressing inherent risks during this crisis.